Evidence map›Paper›PMID 30715566›Full record

Trial reportAnnals of hematology2019

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma.

Yu Cai, Liping Wan, Juan Yang, Jun Zhu, Jieling Jiang, Su Li, Xianmin Song, Chun Wang

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yu CaiDepartment of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.
Liping WanDepartment of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.
Juan YangDepartment of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.
Jun ZhuDepartment of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.
Jieling JiangDepartment of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.
Su LiDepartment of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.
Xianmin SongDepartment of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China. shongxm@139.com.
Chun WangDepartment of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China. wangchunsgh@126.com.
Shanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the strategy of using high-dose etoposide mobilization followed by autologous peripheral blood stem cell transplantation (APBSCT) in patients with diffuse large B cell lymphoma (DLBCL) refractory to rituximab-based chemotherapy. Forty patients with refractory DLBCL were treated with high-dose etoposide for stem cell mobilization. All patients were in progressive disease (PD) prior to mobilization and underwent high-dose chemotherapy followed by APBSCT. Successful PBSC mobilization was achieved in all patients. Twenty-three patients (57.5%) showed a clinical response to high-dose etoposide. After APBSCT, 17 patients (42.5%) achieved CR. The 2-year progression-free (PFS) and overall survival (OS) rate were higher in patients responding to high-dose etoposide (64.1% and 77.7%) compared to those without response (11.8% and 11.8%; P < 0.001 for both). The response to high-dose etoposide mobilization therapy was an independent prognostic factor for CR achievement, PFS and OS after APBSCT. High-dose etoposide mobilization chemotherapy followed by APBSCT could rescue a proportion of patients with refractory DLBCL who responded to etoposide mobilization regimen.

Indexed as

Hematopoietic Stem Cell MobilizationPeripheral Blood Stem Cell TransplantationAdolescentAdultAutograftsDisease-Free SurvivalDrug Resistance, NeoplasmEtoposideFemaleFollow-Up StudiesHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedRituximabSurvival RateEtoposideRituximabAutologous peripheral blood stem cell transplantationDiffuse large B cell lymphomaHigh-dose etoposideRefractory

Identifiers

PMID30715566
PMCPMC6423309
OpenAlexW2912936747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.